489.10
3.21 (0.66%)
| Previous Close | 485.89 |
| Open | 492.23 |
| Volume | 1,205,470 |
| Avg. Volume (3M) | 1,539,587 |
| Market Cap | 125,738,311,680 |
| Price / Earnings (Forward) | 27.78 |
| Price / Sales | 11.45 |
| Price / Book | 7.66 |
| 52 Weeks Range | |
| Earnings Date | 5 May 2025 |
| Profit Margin | -4.86% |
| Operating Margin (TTM) | 44.98% |
| Diluted EPS (TTM) | -2.10 |
| Quarterly Revenue Growth (YOY) | 15.70% |
| Quarterly Earnings Growth (YOY) | -5.80% |
| Total Debt/Equity (MRQ) | 10.66% |
| Current Ratio (MRQ) | 2.69 |
| Operating Cash Flow (TTM) | -492.60 M |
| Levered Free Cash Flow (TTM) | 2.73 B |
| Return on Assets (TTM) | 12.68% |
| Return on Equity (TTM) | -3.15% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Vertex Pharmaceuticals Incorpor | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | -1.5 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | 0.00 |
|
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Large Value |
| % Held by Insiders | 0.13% |
| % Held by Institutions | 96.08% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 567.00 (B of A Securities, 15.93%) | Buy |
| Median | 467.00 (-4.52%) | |
| Low | 420.00 (RBC Capital, -14.13%) | Hold |
| Average | 488.00 (-0.23%) | |
| Total | 4 Buy, 5 Hold | |
| Avg. Price @ Call | 465.33 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Cantor Fitzgerald | 22 Apr 2025 | 535.00 (9.38%) | Buy | 489.10 |
| 11 Feb 2025 | 480.00 (-1.86%) | Buy | 455.22 | |
| RBC Capital | 01 Apr 2025 | 420.00 (-14.13%) | Hold | 484.74 |
| 20 Feb 2025 | 408.00 (-16.58%) | Hold | 480.33 | |
| B of A Securities | 31 Mar 2025 | 567.00 (15.93%) | Buy | 484.82 |
| Canaccord Genuity | 12 Feb 2025 | 424.00 (-13.31%) | Hold | 453.20 |
| Barclays | 11 Feb 2025 | 467.00 (-4.52%) | Hold | 455.22 |
| HC Wainwright & Co. | 11 Feb 2025 | 550.00 (12.45%) | Buy | 455.22 |
| Morgan Stanley | 11 Feb 2025 | 459.00 (-6.15%) | Hold | 455.22 |
| Scotiabank | 11 Feb 2025 | 450.00 (-7.99%) | Hold | 455.22 |
| Truist Securities | 11 Feb 2025 | 520.00 (6.32%) | Buy | 455.22 |
| Show more | ||||
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |